A three-amino-acid fragment of alpha-MSH that suppresses NF-κB, targets melanocortin receptors in gut tissue, and shows oral bioavailability — unusual for a peptide.
KPV is a tripeptide — just three amino acids: Lysine-Proline-Valine. It's the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring peptide produced by the pituitary gland that plays a central role in regulating inflammation throughout the body.
While α-MSH itself has broad effects including pigmentation and appetite regulation, KPV isolates the anti-inflammatory and gut-protective properties of the parent molecule into a compact, targeted fragment. This makes it one of the most focused anti-inflammatory peptides in the research space — and one of the simplest structurally.
KPV's small size is actually an advantage for gut research. Unlike larger peptides that can be degraded before reaching target tissues, KPV's tripeptide structure is orally bioavailable in some research models — meaning it can be studied via oral route in addition to injection, which is unusual for peptides.
KPV's primary mechanism involves binding to melanocortin receptors — particularly MC1R — which are expressed throughout the body but are especially concentrated in immune cells and intestinal epithelial cells. Activation of MC1R triggers downstream signaling that suppresses NF-κB, the master transcription factor driving inflammatory cytokine production.
In simpler terms: NF-κB is the "on switch" for inflammation. KPV turns it down. When NF-κB is inhibited, production of pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β decreases, reducing both local and systemic inflammatory signaling.
The intestinal epithelium and immune cells of the gut lamina propria express high levels of melanocortin receptors. This means KPV reaches its target receptors efficiently when delivered to gut tissue — whether via oral administration, rectal delivery, or systemic injection. The combination of receptor density and delivery flexibility makes the gut the most well-studied application.
NF-κB dysregulation is central to inflammatory bowel diseases (Crohn's, ulcerative colitis), intestinal permeability ("leaky gut"), and a range of autoimmune conditions. KPV's ability to suppress this pathway without the broad immunosuppression of steroids makes it a research target for conditions where current treatments carry significant side effects.
Both peptides show gut protective effects, but via different mechanisms. BPC-157 works through growth factor upregulation and angiogenesis — it builds tissue. KPV works through NF-κB suppression and MC1R signaling — it quiets inflammation. Many researchers consider them complementary for IBD-related work.
Most peptides are rapidly degraded in the GI tract before reaching systemic circulation. KPV's tripeptide structure makes it unusually resistant to peptidase degradation, and several research models have demonstrated bioactivity via oral administration in gut tissue — though systemic bioavailability via oral route is lower than SubQ injection.
This has led to research into oral KPV formulations and colon-targeted delivery systems (including hydrogel nanoparticles) that could deliver KPV directly to inflamed intestinal tissue. For researchers targeting gut-specific inflammation, oral or rectal administration may be more relevant than systemic injection.
COA-verified vendor pricing with promo codes. Both S1 Research and Tegridy Research carry KPV.
View Pricing → Dosage Calculator